Oligonucleotide Synthesis Market
完整報告名稱與涵蓋範圍
Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report, By Product & Service (Custom Oligo Synthesis Services, GMP Therapeutic Oligo Manufacturing, Synthesis Reagents & Consumables, Synthesis Equipment & Platforms), By Oligo Type (Antisense Oligonucleotides, siRNA, Aptamers, Primers & Probes, Guide RNAs & Other Synthetic Oligos), By Scale (Research, Pilot & Clinical, Commercial), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
Chemically synthesised oligonucleotides underpin two distinct demand streams, and this market captures both: research and diagnostic oligos such as primers, probes and guide RNAs made at small scale in vast catalogue volumes, and therapeutic-grade antisense and siRNA drug substances manufactured under GMP at kilogram scale. Scope covers custom synthesis services, GMP active ingredient manufacturing, phosphoramidites and other synthesis reagents, solid supports, and automated synthesis instruments.
The therapeutic stream is the structural growth story. A steady cadence of approved antisense and siRNA medicines for cardiovascular, hepatic, neurological and rare diseases is pushing programmes from clinical batches toward multi-hundred-kilogram commercial campaigns, straining installed large-scale synthesis capacity and triggering major capital expansions among specialised manufacturers. On the research side, molecular diagnostics, next-generation sequencing workflows and CRISPR experimentation sustain high-volume primer, probe and guide RNA consumption. Technology trends include liquid-phase and enzymatic synthesis routes intended to overcome the yield and sustainability limits of phosphoramidite chemistry at length and scale, greener solvent recovery, and automation that compresses turnaround for custom orders.
North America and Europe dominate therapeutic oligo manufacturing and consume the bulk of catalogue output, while Japan, South Korea, China and India are investing in GMP capacity to serve global sponsors. The competitive structure is two-tiered: a concentrated group of GMP-scale drug substance producers, and a broader, more fragmented field of catalogue and reagent suppliers.
The InsightAce study supplies US$ revenue forecasts for every product and service, oligo type, scale, end user and regional segment over 2026-2035, with trend analysis, competitive landscape review and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Oligonucleotide Synthesis Market Snapshot
Chapter 4. Global Oligonucleotide Synthesis Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Product & Service Estimates & Trend Analysis
5.1. Product & Service & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product & Service:
5.2.1. Custom Oligo Synthesis Services
5.2.2. GMP Therapeutic Oligo Manufacturing
5.2.3. Synthesis Reagents & Consumables
5.2.4. Synthesis Equipment & Platforms
Chapter 6. Market Segmentation 2: By Oligo Type Estimates & Trend Analysis
6.1. Oligo Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Oligo Type:
6.2.1. Antisense Oligonucleotides
6.2.2. siRNA
6.2.3. Aptamers
6.2.4. Primers & Probes
6.2.5. Guide RNAs & Other Synthetic Oligos
Chapter 7. Market Segmentation 3: By Scale Estimates & Trend Analysis
7.1. Scale & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Scale:
7.2.1. Research Scale
7.2.2. Pilot & Clinical Scale
7.2.3. Commercial Scale
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Pharmaceutical & Biotechnology Companies
8.2.2. Diagnostics & Research Laboratories
8.2.3. Academic & Government Institutes
Chapter 9. Oligonucleotide Synthesis Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Agilent Technologies Inc.
11.2. Nitto Avecia
11.3. Bachem Holding AG
11.4. ST Pharm Co. Ltd.
11.5. Integrated DNA Technologies (Danaher)
11.6. Thermo Fisher Scientific Inc.
11.7. Merck KGaA
11.8. GenScript Biotech Corporation
11.9. Twist Bioscience Corporation
11.10. TriLink BioTechnologies (Maravai LifeSciences)
11.11. Eurofins Genomics
11.12. Kaneka Eurogentec S.A.
11.13. LGC Biosearch Technologies
11.14. ChemGenes Corporation
圖表清單 List of Tables & Figures
Table 1. Global Oligonucleotide Synthesis Revenue Forecast by Product & Service, 2026-2035 (US$ Mn)
Figure 1. Oligonucleotide Synthesis Value Chain from Phosphoramidites to GMP Drug Substance
Table 2. Global Oligonucleotide Synthesis Revenue Forecast by Oligo Type, 2026-2035 (US$ Mn)
Figure 2. Global Oligonucleotide Synthesis Share by Oligo Type, 2026 & 2035
Table 3. Global Oligonucleotide Synthesis Revenue Forecast by Scale, 2026-2035 (US$ Mn)
Figure 3. Approved and Late-Stage Antisense and siRNA Therapeutics Pipeline Overview
Table 4. Global Oligonucleotide Synthesis Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. GMP Oligonucleotide Manufacturing Capacity Expansion Tracker
Table 5. North America Oligonucleotide Synthesis Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Enzymatic and Liquid-Phase Synthesis Technology Readiness Assessment
Table 6. Europe Oligonucleotide Synthesis Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Oligonucleotide Synthesis Growth Opportunity Analysis
Table 7. Asia Pacific Oligonucleotide Synthesis Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Oligonucleotide Synthesis Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們